Turning Point Gets FDA OK for Elzovantinib/Aumolertinib Combo Study

By Colin Kellaher

Turning Point Therapeutics Inc. on Thursday said it received U.S. Food and Drug Administration approval to study its elzovantinib drug candidate in combination with EQRx Inc.'s aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer.

The San Diego clinical-stage oncology company said it expects to initiate the Phase 1b/2 study in mid-2022.

Aumolertinib is approved in China for first-line treatment of EGFR mutant non-small cell lung cancer and second-line treatment of T790M+ EGFR mutant non-small cell lung cancer.

Turning Point said the study will evaluate the safety, tolerability and preliminary efficacy of the combination elzovantinib/aumolertinib regimen.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

01-20-22 0937ET